PHILADELPHIA – Giving patients a single shot of colchicine before percutaneous coronary intervention was found to favorably impact inflammatory biomarkers linked to vascular injury, but not to lower the risk of procedure-related myocardial injury, according to results of the COLCHICINE-PCI randomized trial reported at the American Heart Association scientific sessions.
This is the first study to evaluate pre-PCI colchicine versus placebo on markers of myocardial injury and inflammation, said, of Veterans Affairs New York Harbor Healthcare System and New York University.
“More work is needed to determine the optimal dosing and timing regimen of colchicine administration in patients undergoing PCI,” Dr. Shah said in an interview. “In this study, we saw inflammatory markers decrease around the 24-hour time point post PCI, so an earlier start to preprocedural colchicine regimen warrants further investigation.” The study found that pre-PCI colchicine attenuated increases in interleukin-6 and high-sensitivity C-reactive protein (CRP) concentrations at 24 hours post PCI, Dr. Shah said.
The results followed by a day the presentation of results from the COLCOT trial (Colchicine Cardiovascular Outcomes Trial) that showed a 23% reduction in cardiovascular events in patients with coronary disease on colchicine 0.5 mg daily vs. placebo (N Engl J Med. 2019 Nov 16.), as , PhD, of the University of Toronto noted in his discussant comments. COLCHICINE-PCI “has important implications, since patients with acute coronary syndrome often have variable biomarker responses, as biomarkers often function as acute-phase reactants in that setting.”
The COLCHICINE-PCI study of 400 patients investigated oral 1.8 mg colchicine given 1-2 hours before the patient went to the cath lab. The drug was given in a 1.2-mg dose followed an hour later by an 0.6-mg dose. Patients received placebo at the same intervals. An inflammatory biomarker substudy of 280 patients evaluated differences in plasma interleukin-6 levels at baseline and 1 hour post PCI, as well as other key biomarkers at longer intervals.
The primary outcome of PCI-related myocardial injury showed no statistically significant difference between the two groups, Dr. Shah said: 57.3% for colchicine and 64.2% for placebo (P = 0.19). The same was true of 30-day major adverse cardiovascular events, she said: 11.7% and 12.9% for the treatment and placebo groups, respectively (P = 0.82). Rates of PCI-related MI were also similar between the two groups.
However, the biomarker substudy told a different story. IL-6 levels in the treatment group were stable at 1 and 6-8 hours post PCI. “However, at 22-24 hours we see a significant attenuation in the rise of IL-6 with colchicine,” she said.
While IL-beta levels showed no deviation after PCI, the colchicine group showed a noticeable attenuation in the rise of high-sensitivity CRP levels at 22-24 hours.
“This is the first study to demonstrate that an oral load of colchicine prevents a rise of inflammatory markers in an acute-injury setting,” Dr. Shah said.
While results of the COLCOT trial affirmed a “resounding yes” for the use of colchicine in patients who’ve had a recent MI, Dr. Verma said the COLCHICINE-PCI results did not give as clear an answer.
“What about pre- or peri-PCI?” he said. “I don’t think we’re there yet, but I do think that more studies are needed that target residual inflammatory risk and potentially couple an acute loading dose with a chronic, ongoing treatment.” Results from higher-risk primary prevention studies, such as theof a colchicine-spironolactone combination in patients with STEMI having PCI, are needed, he said.
Dr. Shah disclosed financial relationships with Phillips Volcano and Radux. The VA Office of Research and Development and AHA provided grant funding and Takeda Pharmaceuticals provided the drug.
SOURCE: Shah B. AHA 2019, .